Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

@article{Ciani2014ValidationOS,
  title={Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.},
  author={O. Ciani and S. Davis and P. Tappenden and R. Garside and K. Stein and A. Cantrell and E. D. Saad and M. Buyse and R. Taylor},
  journal={International journal of technology assessment in health care},
  year={2014},
  volume={30 3},
  pages={
          312-24
        }
}
  • O. Ciani, S. Davis, +6 authors R. Taylor
  • Published 2014
  • Medicine
  • International journal of technology assessment in health care
  • OBJECTIVES Licensing of, and coverage decisions on, new therapies should rely on evidence from patient-relevant endpoints such as overall survival (OS). Nevertheless, evidence from surrogate endpoints may also be useful, as it may not only expedite the regulatory approval of new therapies but also inform coverage decisions. It is, therefore, essential that candidate surrogate endpoints be properly validated. However, there is no consensus on statistical methods for such validation and on how… CONTINUE READING

    Tables and Topics from this paper.

    QALYs as a measure of value in cancer
    • 26

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 73 REFERENCES
    Bias in meta-analysis detected by a simple, graphical test
    • 28,974
    • PDF
    Surrogate End Points in Clinical Trials: Are We Being Misled?
    • 1,376
    • PDF
    The validation of surrogate endpoints in meta-analyses of randomized experiments.
    • 430
    • PDF